Glenmede Trust’s Aegerion Pharmaceuticals AEGR Stock Holding History

Glenmede Trust’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-65	Closed	–	–	2827
2016 Q1	$0	Hold	65	–	–	﹤0.01%	2798
2015 Q4	$0	Hold	65	–	–	﹤0.01%	2859
2015 Q3	$0	Buy	+65	New	+$1.16K	﹤0.01%	2918

Other funds holding AEGR

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Glenmede Trust's AEGR Position: Q2 2016 in Review

Glenmede Trust sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 65 shares.

Glenmede Trust first reported a position in AEGR in Q3 2015 and held it in 3 quarters. The position peaked at $0 in Q1 2016. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

Glenmede Trust reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Glenmede Trust sold 65 Aegerion Pharmaceuticals shares in Q2 2016.
Glenmede Trust first reported a position in Aegerion Pharmaceuticals in Q3 2015 and held it in 3 quarters.
Glenmede Trust's Aegerion Pharmaceuticals position peaked at $0 in Q1 2016.
71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on Glenmede Trust's 13F filing for Q2 2016, filed 5 Aug 2016.